Ashraf Elshami, MD
Pulmonary Disease · Sioux Falls, SDNPI 1306842968
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 97.7% of the total across 76 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 22 manufacturers, the largest accounting for just 19.8% — the pattern of someone who eats at a lot of different presentations.
Across 76 payments — averaging $27.28 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Baxter Healthcare$410
- Advanced Respiratory, Inc$329
- United Therapeutics Corporation$145
- AstraZeneca$142
- Amgen$130
- Actelion Pharmaceuticals US, Inc.$124
- plus $792 from 16 others
What the payments were for
- Food & beverage$2,02698%
- Education$472%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Baxter Healthcare | 12 | $410 |
| Advanced Respiratory, Inc | 11 | $329 |
| United Therapeutics Corporation | 2 | $145 |
| AstraZeneca | 9 | $142 |
| Amgen | 2 | $130 |
| Actelion Pharmaceuticals US, Inc. | 1 | $124 |
| Regeneron Healthcare Solutions, Inc. | 2 | $107 |
| Grifols USA, LLC | 5 | $101 |
| Insmed, Inc. | 5 | $92 |
| Boehringer Ingelheim | 6 | $82 |
| Genentech USA, Inc. | 1 | $74 |
| Viatris Specialty LLC | 2 | $49 |
| GSK | 3 | $46 |
| Inspire Medical Systems, Inc. | 2 | $45 |
| Merck | 3 | $36 |
| Mylan Specialty L.p. | 2 | $36 |
| Jazz Pharmaceuticals Inc. | 2 | $34 |
| Axsome Therapeutics, Inc. | 1 | $22 |
| Seqirus USA Inc | 1 | $20 |
| Sunovion Pharmaceuticals Inc. | 2 | $20 |
| Phadia US Inc. | 1 | $15 |
| Harmony Biosciences LLC | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$2,073 in reported general payments places this provider in the 60th percentile of 35 pulmonary disease providers in South Dakota.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 601 | $478,357 |
| Sodium Oxybate | 17 | $298,292 |
| Breo ElliptaFluticasone/Vilanterol | 231 | $116,242 |
| Spiriva RespimatTiotropium Bromide | 169 | $92,686 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 123 | $88,047 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 131 | $76,109 |
| Dupixent SyringeDupilumab | 16 | $62,455 |
| Incruse ElliptaUmeclidinium Bromide | 80 | $34,989 |
| Arnuity ElliptaFluticasone Furoate | 98 | $31,828 |
| Advair HfaFluticasone Propion/Salmeterol | 60 | $26,765 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 95 | $13,299 |
| DuleraMometasone/Formoterol | 37 | $13,049 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 363 | $11,562 |
| SymbicortBudesonide/Formoterol Fumarate | 29 | $10,252 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 39 | $10,196 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Incruse Ellipta, Arnuity Ellipta | $46 | $737,5261,141 claims |
| AstraZenecaBreztri Aerosphere, Symbicort, Pulmicort Flexhaler | $142 | $105,012172 claims |
| Boehringer IngelheimSpiriva Respimat | $82 | $92,686169 claims |
| MerckDulera | $36 | $13,04937 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 35 pulmonary disease providers in South Dakota.
Other pulmonary disease in Sioux Falls
- Joevasanth DevasahayamSioux Falls$8K
- Matthew TaylorSioux Falls$8K
- Fady JamousSioux Falls$6K
- Rizan HajalSioux Falls$5K
- Kaitlin BranickSioux Falls$5K
- Anna PlemmonsSioux Falls$3K
- Mohammed AwadSioux Falls$2K
- John YuSioux Falls$2K
- Rajaganesh RajagopalanSioux Falls$964
- Ross BaconSioux Falls$599
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.